Pathway to Stop Diabetes
Pathway to Stop Diabetes has a simple, yet revolutionary goal: to find scientists at the peak of their creativity and provide them with the flexibility and resources they need on the road to breakthrough discoveries. We attract and retain brilliant scientists in diabetes. Our three areas of focus—awarding research grants, providing access to scientific and career mentoring from leading diabetes researchers, and creating a diabetes think tank—are each key components of a unique formula to cultivate the next generation of leaders, whose discoveries will stop diabetes and all of its burdens once and for all.
Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to: 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) determine the association of current or newly developed self-reported measures of IAH with counter-regulatory responses to elucidate the heterogeneity in restoration of hypoglycemia awareness.
Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individual’s ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known.
Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites a single cooperative agreement application for a data coordinating center that first establishes a biorepository of human cardiovascular (CV) tissue and then serves as a coordinating center resource for discovery and mechanistic research to increase our knowledge of the CV complications of type 1 diabetes (T1D).
Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)
This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease.
Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed)
This FOA invites applications for continuation of the Collaborative Islet Transplantation Registry (CITR).
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to better understand youth-onset type 2 diabetes.
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Clinical Centers (U01 Clinical Trial Not Allowed)
The purpose of this FOA is to create a clinical consortium to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty.
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)
This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.
Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)
The National Cancer Institute (NCI) invites research grant applicationsfor transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program.